Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?
Novel Treatments, Medical Community, Challenges and Barriers, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat, Clinical Research, Obstacles to Better Outcomes, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife Novel Treatments, Medical Community, Challenges and Barriers, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat, Clinical Research, Obstacles to Better Outcomes, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife

Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?

Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.

Read More
Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin
Novel Treatments, Medical Community, Challenges and Barriers, MBC Research Funding, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat, Obstacles to Better Outcomes, Patient Reported Outcomes and Out of the Box Treatment Options, Clinical Research Our MBClife Novel Treatments, Medical Community, Challenges and Barriers, MBC Research Funding, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat, Obstacles to Better Outcomes, Patient Reported Outcomes and Out of the Box Treatment Options, Clinical Research Our MBClife

Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin

The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.

Read More